ClinicalTrials.gg
TerminatedNCT05075304Updated May 21, 2024

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

A Phase 1 interventional study of BDB-001 injection and BDB-001 injection in COVID-19, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Terminated at 4 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Feb 2020, registered Aug 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.

Enrollment
298th of 330
18 · median 200
Started
2020
with 122 others
Phase 1
67 of 472
7 open now
Registered
169th of 472
by date

Among the 472 studies in COVID-19 with a site in China, this one is the 298th largest by enrollment of the 330 interventional ones that give a count, is one of 123 that started in 2020, is one of 67 in phase 1, and was the 169th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 472 studies in COVID-19 with a site in China, or all of them as a file.
02

Study summary

This open, multi-center, multiple ascending dose study was designed to evaluate the safety, tolerability, preliminary efficacy and PK/PD of BDB-001 injection in patients with mild, or general COVID-19.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18≤ age ≤60, 18 kg/m2 ≤ ≤28 kg/m2, male or female;
  • Diagnosed with 2019-nCoV infection and classified clinically as mild or general;
  • Agreed not to participate in other clinical studies before completing this study;
  • With the subject's consent and signed form by the subject or his/her legal representative.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with 2019-nCoV infection and classified clinically as severe or critical severe; severe pneumonia or acute respiratory distress syndrome, sepsis and septic shock;
  • The disease would deteriorate significantly within 48 hours judged by the investigators;
  • Immunodeficiency or immune related diseases not suitable for participation judged by the investigators (such as diseases, IgG4 related diseases, allergic alveolitis, vasculitis, etc);
  • Lymphocyte count \<0.5×109/L;
  • Neutropenia history (neutrophil absolute count was less than 2×109/L in adults), except for infection;
  • D- dimer >2000 µg/L;
  • Severe history of lung diseases, such as , lung cancer, tuberculosis, etc., history of heart disease: unstable angina pectoris, myocardial infarction, cardiac surgery, cardiac function≥ grade 3 ( classification), serious history of liver disease (such as score ≥grade C), serious renal disease history, such as renal insufficiency ( ≤ 15ml/min/1.73m2), etc;
  • The subjects used the following drugs within 2 weeks (including 2 weeks) before screening:

    1. Calcineurin inhibitors (such as cyclosporin and tacrolimus);
    2. Proliferation inhibitors (such as everolimus, sirolimus, etc);
    3. anti-metabolic agents (such as mycophenolate mofetil, mycophenolic acid, purine sulfate, etc);
  • Pregnant or lactating women.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    A low dose of BDB-001

    6 patients administered low dose of BDB-001 injection

    Drug: BDB-001 injection

  • Experimental
    A intermediate dose of BDB-001

    6 patients administered intermediate dose of BDB-001 injection

    Drug: BDB-001 injection

  • Experimental
    A high dose of BDB-001

    3-6 patients administered high dose of BDB-001 injection

    Drug: BDB-001 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with serious adverse events (SAEs) and non-serious adverse events

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations as judged by physician. Number of participants who had SAEs and non-SAEs are presented.

    Time frame: Up to Day 40

  2. Number of participants with abnormal laboratory tests

    Blood samples were collected for the assessment of laboratory tests. Number of participants with abnormal laboratory tests parameters are presented.

    Time frame: Up to Day 40

  3. Number of participants with physical examination

    Blood samples were collected for the assessment of physical examination. Number of participants with abnormal physical examination parameters are presented.

    Time frame: Up to Day 40

  4. Number of participants with abnormal vital signs

    Vital signs were measured in a semi-supine position after five minutes of rest and included temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP) , heart rate, respiratory rate. Number of participants with abnormality in any vital signs are presented.

    Time frame: Up to Day 40

  5. Number of participants with abnormal electrocardiogram (ECG) findings

    Number of participants with abnormality Abnormal Electrocardiogram (ECG) are presented.

    Time frame: Up to Day 40

  6. Plasma concentration of BDB-001 following intravenous administration

    Blood samples were collected at indicated time points for measurement of Plasma concentrations of BDB-001 following intravenous administration. Pharmacokinetic Population comprised of all participants for whom at least one evaluable pharmacokinetic sample was obtained and analyzed.

    Time frame: Within 60 minutes (prior to start of BDB-001 IV infusion), 10 minutes (end of infusion); at 6, 12,24, 48 hours after end of infusion.

  7. Plasma concentration of ADA

    Time frame: Within 60 minutes (prior to start of the first and second BDB-001 IV infusion), Day 7 24 hours after infusion, day 14.

07

Study locations

4 sites
  • Sanya Central Hospital (Hainan Third People'S Hospital)
    Sanya, Hainan 572000, China
  • Renmin Hospital Of Wuhan University Bubei General Hospital
    Wuhan, Hubei 430060, China
  • General Hospital of Gentral Rheater Command
    Wuhan, Hubei 430070, China
  • Shu Lan (Hangzhou) Hospital
    Hangzhou, Zhejiang 310022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Apr 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2021
First posted
Oct 12, 2021
StartActual
Feb 21, 2020
Primary completionActual
Apr 14, 2020
CompletionActual
Apr 14, 2020
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05075304
Collaborators
Beijing Defengrui Biotechnology Co. Ltd
Responsible party
Sponsor
First posted
Oct 12, 2021
Start date
Feb 21, 2020
Primary completion
Apr 14, 2020
Completion
Apr 14, 2020
Last update
May 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion